Aligos Therapeutics, Inc. (ALGS) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 30.38M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $30.38M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $29.98M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $18.30M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $41.95M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $18.66M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $73.76M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $37.00M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $35.33M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $45.08M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $24.15M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $135.70M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $70.43M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $90.83M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $78.67M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $81.35M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $86.44M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $71.17M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $104.56M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $186.82M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $239.73M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $187.65M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $200.36M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $220.38M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $31.82M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $22.68M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $25.41M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $69.56M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $21.13M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |